Schizophrenia Clinical Trials in Phoenix

Showing 61-78 of 78 trials

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

SchizophreniaPsychotic DisordersBipolar Disorder

Eli Lilly and Company130 participantsStarted Apr 2001

El Centro, California, United States • Jacksonville, Florida, United States • Miami, Florida, United States +13 more locations

COMPLETEDPHASE4290 miles

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012

The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared to quetiapine.

SchizophreniaSchizoaffective Disorder

Eli Lilly and Company340 participantsStarted Jul 2004

Garden Grove, California, United States • La Mesa, California, United States • San Diego, California, United States +22 more locations

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Schizophrenia Trials in Other Cities

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

A Long-Term, Open-Label, Study on Schizophrenia

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Other Conditions in Phoenix